knowledge -WSS

knowledge

author：knowledge 2025-09-29 16:25:48 - browse：66

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： An outdated Medicare rule harms dementia patients with anxiety

entertainment

hotspot

WSS

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Congress needs to close a vaccine

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

BD to buy Edwards patient monitoring unit for $4.2 billion

Trump team launching legal defense fund to help pay legal bills

House GOP plan to stem drug shortages differs from Democrats’

focus

knowledge

knowledge

Hollywood unions extend contract negotiations for actors

BD to buy Edwards patient monitoring unit for $4.2 billion

Guidelines to prevent youth baseball injuries need more muscle

Fight over Supreme Court dialysis ruling puts kidney patients at risk

In Memoriam: Notable people who died in 2023

FDA approves Moderna’s RSV vaccine, its second licensed product

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

BD to buy Edwards patient monitoring unit for $4.2 billion

Jerome Adams on the need for new antivirals for Covid

Illumina board agrees to spin off Grail, as divestment plans proceed

Wikipedia

HCA says smaller share of spending going to labor

Many immigrants are left out of maternal health programs

House GOP plan to stem drug shortages differs from Democrats’

Doctors increasingly discourage vaping amid mounting health concerns

STAT wants to know your pick for a great summer read or listen

Eli Lilly’s Zepbound improved liver scarring in mid

entertainment

hotspot

hotspot

hotspot